INTS6 Blocking Peptide (N-Term)
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UL03 |
---|---|
Other Accession | Q5JSJ4, Q8BND4, Q2TAF4, Q5U4W6, Q7SYD9, Q6PCM2 |
Gene ID | 26512 |
---|---|
Other Names | Integrator complex subunit 6, Int6, DBI-1, Protein DDX26, Protein deleted in cancer 1, DICE1, INTS6, DBI1, DDX26, DDX26A |
Target/Specificity | The synthetic peptide sequence is selected from aa 155-167 of HUMAN INTS6 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | INTS6 {ECO:0000303|PubMed:33243860, ECO:0000312|HGNC:HGNC:14879} |
---|---|
Function | Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes (PubMed:33243860, PubMed:34004147). The integrator complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the complex terminates transcription by (1) catalyzing dephosphorylation of the C-terminal domain (CTD) of Pol II subunit POLR2A/RPB1 and SUPT5H/SPT5, (2) degrading the exiting nascent RNA transcript via endonuclease activity and (3) promoting the release of Pol II from bound DNA (PubMed:33243860, PubMed:34004147, PubMed:38570683). The integrator complex is also involved in terminating the synthesis of non-coding Pol II transcripts, such as enhancer RNAs (eRNAs), small nuclear RNAs (snRNAs), telomerase RNAs and long non-coding RNAs (lncRNAs) (PubMed:16239144). Within the integrator complex, INTS6 acts as a molecular adapter that promotes assembly of protein phosphatase 2A (PP2A) subunits to the integrator core complex, promoting recruitment of PP2A to transcription pause-release checkpoint (PubMed:33243860, PubMed:34004147). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the integrator complex (PubMed:23904267). May have a tumor suppressor role; an ectopic expression suppressing tumor cell growth (PubMed:15254679, PubMed:16239144). |
Cellular Location | Nucleus. Chromosome Note=Associates with chromatin and transcription pause-release checkpoint. |
Tissue Location | Widely expressed. Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Component of the Integrator complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes. May have a tumor suppressor role; an ectopic expression suppressing tumor cell growth.
References
Wieland I.,et al.Oncogene 18:4530-4537(1999).
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Dunham A.,et al.Nature 428:522-528(2004).
Hoff H.B. III,et al.Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
Wieland I.,et al.Oncol. Res. 12:491-500(2001).

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.